DURYSTA

Peak

bimatoprost

NDAOPHTHALMICIMPLANT
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional).…

Pharmacologic Class:

Prostaglandin Analog

Clinical Trials (5)

NCT05729594Phase 1Completed

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Started Feb 2023
NCT05397600Phase 3Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Started Jun 2022
NCT04647214N/ACompleted

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

Started Mar 2021
220 enrolled
Open-angle GlaucomaOcular Hypertension
NCT04285580Phase 3Completed

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Started Jun 2020
37 enrolled
Open-Angle GlaucomaOcular Hypertension
NCT03891446Phase 3Active Not Recruiting

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Started Mar 2019
455 enrolled
Open-Angle GlaucomaOcular Hypertension

Loss of Exclusivity

LOE Date
Oct 31, 2034
105 months away
Patent Expiry
Oct 31, 2034

Patent Records (5)

Patent #ExpiryTypeUse Code
9149428
Dec 19, 2026
Product
10441543
Dec 19, 2026
Product
8206737
Apr 7, 2027
U-2759
7799336
Apr 24, 2029
Product
8629185
Jul 15, 2031
SubstanceProduct